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Introduction 
There is considerable uncertainty regarding the best intravenous agent to use for treatment of acute 
severe paediatric asthma.1 2 This uncertainty is due to a lack of robust evidence, a large existing variation 
in practice,2 differences in the definition of severe acute asthma and differing thresholds to initiate 
treatment. 
Current evidence of variation in treatment of acute severe asthma in children includes a recent UK and 
Ireland study, which identified more than 30 different intravenous treatment regimens in 110 children 
presenting to 24 paediatric EDs.3 Similarly, an Australasian survey of paediatric emergency clinicians 
demonstrated highly variable practice in self-reported treatment of severe to critical asthma in children.4 
In addition to this large variation in practice, evidence from completed studies is difficult to  
Key messages 
What is already known on this 
subject ► Despite the fact that 
there are a number of 
randomised trials on intravenous 
therapy for paediatric severe 
asthma, there remains 
considerable variation in 
treatment. 
► Variation in outcome measures 
and lack of patient-centred 
outcomes are likely to 
contribute to the uncertainties 
regarding this treatment. 
What this study adds 
► In this systematic review of 
randomised studies of intravenous 
bronchodilator therapy we found 
56 different measures of primary 
outcome, the most common being 
a clinical asthma score (23/56; 
41%), with pulmonary function 
tests (11/56; 20%) and length of 
stay measures (9/56; 16%) also 
featuring highly. 
► Few studies considered health 
economic data (2/39; 5%) and none 
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considered clinician and patient 
perspectives. 
► The development of a core 
outcome set is required to allow for 
meaningful, comparable studies to 
be conducted. 
compare due to differences in outcome measures between trials.2 5 6 No current consensus guidelines on 
the conduct and reporting of trials in acute severe paediatric asthma exist. Patient-reported outcomes 
and those related to health economics are limited. Previous Cochrane reviews have recommended 
consensus on core outcomes7 and a need to focus on clinically important outcomes such as admission to 
intensive care, hospital admission, length of stay and relapse rates.8 
This systematic review aims to determine the variability of current primary and secondary outcomes 
used in comparative studies of intravenous bronchodilators for acute severe paediatric asthma. It is hoped 
this will lay the foundation for further discussion around the utility of these outcomes, and how the 
research community could move towards a useful, inclusive, defined set of core research outcomes for 
this group of patients. 
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Methods 
This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement.9  
Eligibility Criteria 
Studies were deemed eligible if they included children (defined as younger than 18 years) and had a 
randomised trial design comparing an intravenous bronchodilator treatment to another bronchodilator 
or to placebo in acute severe asthma. All languages were considered. For the search of the WHO clinical 
trials database, trials that were registered even if not yet active were included. As our research question 
focused on acute severe asthma in children, we excluded studies that included a combination of adults 
and children where the paediatric patients were unable to be separated from the adult patients. 
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Information sources 
We systematically searched MEDLINE, EMBASE, Cochrane CENTRAL databases and the WHO International 
Clinical Trials Registry Platform for randomised trials in children (aged 1–18 years) with acute severe 
asthma. Search was performed on 7 January 2017 and repeated on 6 September 2018 to identify any new 
studies prior to publication of the review. All databases were searched from inception of database. A full 
search strategy for each database is listed in online supplementary table 1.  
 
Figure 1 PRISMA flow diagram. 
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Study selection 
Search results were reviewed independently by two authors (CSG and SC) and those deemed not to meet 
inclusion criteria by title and abstract were excluded. Full-text articles were then reviewed to determine 
eligibility. Any disagreement was resolved by discussion and reaching consensus. For all relevant Cochrane 
reviews and meta-analyses, individual studies were obtained, and assessed against our inclusion criteria. 
Two non-English papers were translated using Google Translate (Google, Mountain View, California, USA), 
with information verified from clinical trial registries where possible.  
 
Data collection process 
The following characteristics were recorded for each study: geographic location, year of publication, 
number of patients, primary, secondary and other outcomes used, study interventions including dosing 
and timing of medication administered. 
  
Table 1 Frequency of primary and secondary 
outcome measures 
 Primary outcome  secondary 
outcome 
Outcome measure (n=56) (n=60) 
Clinical response to treatment 
  Asthma scores 23 (40%) 5 (8%) 
  Bedside pulmonary function tests 11 (20%)
 6 (11%) 
  Adverse events 2 (4%) 11 (17%) 
  Physical examination findings 2 (4%) 1 
(2%) 
  Vital signs 4 (7%) 2 (4%) 
  Duration of oxygen therapy 2 (4%) 
 Dosage of inhaled beta agonist   
 required 3 (3%) 7 (12%) 
  Need for second-line therapy 2 (4%) 
Length of stay measures 
  Disposition of patient after trial  
 drug given 1 (2%) 5 (8%) 
  Admission rate to hospital1 (2%) 2 (4%) 
 Total hospital length of stay 5 (9%) 7 
(12%) 
  ED length of stay 2 (4%) 2 (4%) 
 Intensive care length of stay  6 (8%) 
  Intensive care admission rate 1 (2%) 
  Representation rate within same  
 illness 1 (2%) 
Health economic measures1 (2%) 1 (2%) 
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These data were collected independently by two authors and were recorded on a Microsoft Excel 
spreadsheet (Excel 2008; Microsoft; Redmond, Washington, USA). Any disagreement regarding extraction 
of data or outcome categorisation was resolved by discussion. For all studies that reported a clinical 
asthma score, the Methods section of the paper was reviewed to identify the specific asthma clinical score 
used, and the timing and cut-off used to determine patient improvement was recorded. In addition, all 
outcome measures were recorded as listed in the paper; if the paper reported two primary outcomes 
these were both recorded as primary outcomes and used in data analysis. Given that this systematic 
review was designed solely to describe and analyse outcome measures there were no data collected on 
the design or the quality of the study. 
Results 
From the 1293 studies identified across the databases, 197 duplicates were excluded; review of titles and 
abstracts yielded 89 papers that were selected for full-text review. Thirty-five published papers and four 
registered study protocols were included for analysis. The selection of articles is outlined in the PRISMA 
diagram (figure 1). 
 
The 35 published studies ranged in date from 1971 to 2017, with ongoing recruitment of patients in the 
four registered study protocols. The number of patients within the completed studies ranged from 21 to 
276 with a median (IQR) of 44 (29–56), and involved eight different medications (online supplementary 
table 2). Of the studies, 10 (29%) did not include any teenage patients, defined as being of 12–18 years, 
and 10 (29%) did not include any preschool patients, defined as being less than 6 years. Medication doses 
and administration varied between studies, with the same medication being given by bolus or infusion, at 
different time intervals, or for different infusion durations. Aminophylline, which is featured in 12 
randomised trials, did not have any two trials which used the same dosage or timing of medication. Two 
aminophylline studies did not specify details of drug administration (online supplementary table 3). There 
was also a difference in the capturing of adverse events with 6/13 (45%) trials involving magnesium sulfate 
including this as an outcome measure, compared with 9/12 (75%) and 4/4 (100%) studies involving 
aminophylline and theophylline, respectively (online supplementary table 4). 
There were a total of 56 primary outcomes listed across the 39 studies. The majority (23/38; 60%) of 
studies listed one primary outcome. Eleven studies (29%) reported two primary outcomes, four (11%) 
reported three primary outcomes and one study (3%) reported four primary outcomes. The most 
commonly used primary outcome was a clinical asthma score (23/56; 41%). Other identified primary 
outcomes included bedside tests of respiratory function (11/56; 35%), and various length of stay measures 
(9/56; 16%), including hospital, ED or intensive care length of stay. Two trials (2/56; 4%) included oxygen 
saturation. The majority of secondary and other outcomes listed were length of stay measures and 
adverse events. No study included a patient-reported variable as an outcome measure and only two 
studies incorporated cost-effectiveness measures. The frequency of primary and secondary outcomes is 
outlined in table 1. A full list of outcomes measures by study is presented in the online supplementary 
table 5. 
There were at least eight different clinical asthma scores used (table 2); in addition, six studies described 
use of an asthma score but did not provide sufficient detail to determine which score was used. Timing of 
measurement varied. Scores that had the same label (eg, the ‘clinical asthma score modified from the 
pulmonary index’) did not necessarily measure the same components. In addition, within the same score, 
the cut-off used to define success of the administered treatment varied between studies. 
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Secondary outcomes for most studies comprised more than one measure with a total of 60 outcomes 
identified across the 39 studies. The most common secondary outcome measures related to hospital 
length of stay (24/60; 40%) and adverse events (11/60; 18%). Additional outcomes included those relating 
to clinical asthma scores, bedside pulmonary function tests, frequency or type of asthma medications 
administered, physical examination findings and vital signs. 
Discussion 
This systematic review demonstrates that studies of intravenous bronchodilator therapy for children with 
acute severe paediatric asthma have used inconsistent and variable outcome measures. Therefore, 
uncertainty exists for clinicians who work in an ED about which intravenous treatment to use and the 
optimum regime. Additionally, we do not know what is most important to patients and families, and have 
little information to explain how the treatment we are providing will benefit them. Finally, we are unable, 
with current data, to establish or compare the cost-effectiveness of varying treatment regimes. In an 
uncommon condition, such as acute severe paediatric asthma, creating reliable data is dependent on the 
ability for study results to be compared and combined in systematic reviews and meta-analyses; currently, 
the lack of comparable outcomes makes this very difficult. 
The most commonly recorded primary outcome was a clinical asthma score. A valid and reliable bedside 
clinical assessment of severity in children is potentially useful, as it allows for quantification of severity of 
illness and is a way to measure improvement. In addition, most international asthma guidelines suggest 
use of clinical scores to assess severity and guide treatment response, although it is noteworthy that none 
recommends a specific score.10 11A recent systematic review of clinical scores for the assessment of acute 
dyspnoea in wheezing children found that none of over 20 scores examined had been sufficiently 
validated to allow for clinically meaningful use in this population.12 The Cochrane review by Mitra and 
colleagues reiterates  
 
Table 2 Clinical asthma scores used as primary outcome measures  
 
 
Timing 
of score 
in hours 
 
Total 
numb
er of 
studie
s 
Pulmonary index 
score 
Allen and Macias27 0, 0.5, 
1.5, 2 
Percentage of patients with reduction in 
score by 2 over 2-hour time of drug 
infusion 
4 
 Bien et al28 0, 8, 16, 
24  
Difference in score between treatment and 
placebo at defined intervals 
 
 Carter et al29 0, 1, 3, 6, 
12, 24, 
36  
Difference in score between intervention 
and placebo group at time intervals  
 
 Scarfone et al30 0.33, 0.5, 
0.66, 1,  
1.33, 2  
Degree of change over 120 min   
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Clinical asthma 
severity score of 
Asthma Australia 
Browne et al31 2, 4, 8, 
12, 24 
Percentage with persistent moderate 
asthma at specified time intervals 
1 
Clinical asthma 
score, modified 
from pulmonary 
index score 
Bogie et al32 Devi 
et al33 
0, 1, 2, 4, 
6, 12, 24 
0.5, 1, 2, 
3, 7 
Mean improvement in score over 24 hours 
Improvement in score at time intervals 
measured after cessation of drug infusion 
6 
 DiGiulio et al34 0 then 
twice 
daily  
Time to reach study discharge criteria score 
of 2 and rate of improvement  
 
 Nuhoğlu et al35 2, 6, 12 
and 24 
hours  
Difference in score at 24 hours   
 Singhi et al36 1  hour  Treatment success, as defined by 
improvement of 4 or more points in score 1 
hour after drug commencement  
 
 Wheeler et al13 3, 6, 9, 
12, 24 
and 
every 12 
hours 
after  
Score improvement from admission to 
discharge from intensive care  
 
Asthma severity 
score by Bishop 
et al37  
Roberts et al38 0, 1, 2, 6, 
12, 24 
Difference in score at 2 and 6.5 hours 1 
Wood and 
Downe asthma 
score 
Gürkan et al39 0.25, 0.5, 
0.75,  
1, 1.25, 
1.5  
Difference in score between groups 3 
 Watanatham et al40 0.33, 
0.66, 1, 
2, 3, 4 
Comparative score between groups at 60 
min 
 
 Daengsuwan and 
Watanatham41 
0.20, 
0.40, 1, 
2, 4 
Comparative score between groups at 60 
min 
 
Modified Wood 
and Downe 
asthma score 
Ream et al42 Not 
specified 
Time to score equal to or less than 3 1 
Asthma score 
not specified 
Hambleton and Stone43 1, 2, 4, 6, 
12, 18, 
24 
Mean value of score over first 24 hours 6 
 Hussein et al44 Not 
specified 
Difference in score between two groups—
timing not specified 
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these concerns, commenting that the changes in clinical scores remain largely invalidated against changes 
in lung function.8 As such, further studies are required to improve the evidence base supporting bedside 
scores of childhood asthma, with a view to reducing the number of different scores currently used, and 
achieving better understanding of the clinical relevance of such scores.12 
We also suggest that health economic measures be incorporated into the core outcome set (COS). Only 
two studies considered health economics data as an outcome.13 14 Wheeler and colleagues compared 
medication and blood-level monitoring costs,13 and Irazuzta and colleagues calculated savings based on 
earlier discharge in the treatment arm.14 Assessing the cost of the treatment is likely to become 
increasingly important in any study design. This is highlighted in a recent paper by Petrou and colleagues15 
which estimated the cost-effectiveness of nebulised magnesium sulfate in addition to usual care in acute 
paediatric asthma.16 A method to incorporate economic value outcomes alongside clinical ones has been 
proposed by Ramsey and colleagues.17 
Other important measures of the effect of acute asthma treatment include hospital length of stay and 
intensive care unit admission. However, in the current studies, various measures were employed, 
including actual time to discharge and time for readiness for discharge, both for ED, hospital and intensive 
care stays. The definition of the time for readiness for discharge also varied between studies. With such 
variability, some agreement on length of stay parameters that are important to both clinicians and 
patients is needed. 
We therefore suggest that a core set of outcomes be developed. This drive for consistent outcomes in 
clinical trials is reflected in the wider global research community.18 The Core Outcome Measures in 
Effectiveness Trials initiative is a programme that promotes the development of COS and a practical 
guideline on how to develop such core outcomes has recently been. published.19 20 There are some 
examples of illnesses where COS have already been developed in the paediatric population including 
rheumatoid arthritis21 and eczema.22 
In addition, obtaining the views of patients, caregivers and clinicians is vital, and there have been recent 
publications focusing on both the importance of, and how to include, patient-focused outcomes. This is 
exemplified by the recent extension of the Consolidated Standards of Reporting Trials (CONSORT) 
statement, the CONSORT Patient Reported Outcomes.23 To our knowledge, there is no literature on 
including patient-focused outcomes in acute severe paediatric asthma and no studies in our systematic 
review included such outcomes. 
Some literature exists in the area of care of children who use regular asthma medications as reported 
by Sinha and colleagues.24 They used a modified Delphi process to identify outcomes relevant to clinicians, 
 Naao et al45 At 24 
hours  
Symptom score at 24 hours   
 Needleman et al46 12 hourly  Overall improvement in score in 
comparative groups 
 
 Pierson et al47 Not 
specified  
Not specified   
 Boeschoten48 Not 
specified  
Reduction by 2 points at 1  hour   
 
3 hours 
0.5, 1, 1.5, 2, 2.5, 3, 24 Change in score at  
1  
 
   
 9 
parents and young people, and found that daytime and nocturnal symptoms, exacerbations, quality of life 
and mortality were important outcomes. Although these outcomes focus on treatment success with 
preventer medication, they may have some applicability to children presenting with acute severe 
paediatric asthma. However, other outcomes may be more pertinent in the acute setting, including 
medication side effects, need for interhospital transfer, intensive care admission and/or mechanical 
ventilation, healthcare costs and duration of hospitalisation. To progress research in this area, we suggest 
that the views of patients, carers and families be obtained using interviews, focus groups and/or surveys,25 
in order to develop a set of core outcomes in acute severe paediatric asthma. 
 
Limitations 
This systematic review is limited to studies of children with acute severe paediatric asthma requiring 
intravenous bronchodilator therapy. It was beyond the scope of our review to determine comparative 
effectiveness of asthma therapies. Recently, a protocol for an overview of Cochrane reviews for 
interventions for escalation of therapy for acute exacerbations of asthma in children was published.26 This 
may provide more information regarding comparative effectiveness of various acute asthma treatments 
in this setting. 
There is potential selection bias relating to study inclusion, which was minimised by two authors 
selecting studies independently and resolving differences by consensus. Data collection was also 
completed independently, by clearly defined methods, which were registered prior to data analysis. This 
review might also be affected by publication bias with only positive studies being published in trials on 
comparative intravenous therapy, although we attempted to reduce the impact of such bias by conducting 
additional searches in relevant clinical trial registries.  
 
Conclusion 
Trials of intravenous bronchodilator therapy for acute severe paediatric asthma demonstrate significant 
variability in major outcome measures including choice of asthma clinical scores, length of stay 
parameters, limited consideration of health economics and an absence of patient-focused outcomes. 
Given this heterogeneity we recommend development of a COS that can be used in trials of intravenous 
therapy for acute severe paediatric asthma. This will inform the design of subsequent randomised trials, 
which would allow for meaningful comparisons between therapies for acute severe paediatric asthma. 
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